Conformationally restricted homotryptamines. part 7: 3- cis -(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 21, 2010, Pages 7564-7572

  King, H Dalton ^a   Meng, Zhaoxing ^a   Deskus, Jeffrey A ^a   Sloan, Charles P ^a   Gao, Qi ^a   Beno, Brett R ^a   Kozlowski, Edward S ^a   Lapaglia, Melissa A ^a   Mattson, Gail K ^a   Molski, Thaddeus F ^a   Taber, Matthew T ^a   Lodge, Nicholas J ^a   Mattson, Ronald J ^a   MacOr, John E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DICHLOROBENZOYL) 3 (3 OXOCYCLOPENTYL) 1H INDOLE 5 CARBONITRILE; 3 (3 DIMETHYLAMINOCYCLOPENTYL) 1H INDOLE 5 CARBONITRILE; 3 (3 HYDROXYCYCLOPENTYL) 1H INDOLE 5 CARBONITRILE; 3 (3 OXOCYCLOPENTYL) 1H INDOLE 5 CARBONITRILE; 3 (5 FLUORO 1H INDOL 3 YL)CYCLOPENTANONE HYDRO BENZOIN KETAL; 3 [3 [BENZYL(METHYL)AMINO]CYCLOPENTYL] 5 CYANO 1H INDOLE 1 CARBOXYLATE; [3 (5 FLUORO 1H INDOL 3 YL)CYCLOPENTYL]DIMETHYLAMINE; HOMOTRYPTAMINE DERIVATIVE; INDOLE DERIVATIVE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TERT BUTYL 3 [3 [BENZYL(METHYL)AMINO]CYCLOPENTYL] 5 CYANO 1H INDOLE 1 CARBOXYLATE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; FRONTAL CORTEX; MOUSE; NONHUMAN;

ANIMALS; BIOLOGICAL AVAILABILITY; CEREBRAL CORTEX; CYCLOPENTANES; EXTRACELLULAR SPACE; HUMANS; MICRODIALYSIS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RATS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTAMINES;

EID: 78149264951     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100515z     Document Type: Article

References (20)

1. Horst, W. D. Biochemical and physiological processes in brain function and drug actions Handb. Exp. Pharmacol. 2004, 157, 3-33
2. Preskorn, S. H.; Ross, R.; Stanga, C. Y. Selective serotonin reuptake inhibitors Handb. Exp. Pharmacol. 2004, 157, 241-262
3. Spinks, D.; Spinks, G. Serotonin reuptake inhibition: an update on current research strategies Curr. Med. Chem. 2002, 9, 799-810
4. Denhart, D. J.; Mattson, R. J.; Ditta, J. L.; Macor, J. E. One-pot synthesis of homotryptamines from indoles Tetrahedron Lett. 2004, 45, 3803-3805
5. Schmitz, W. D.; Denhart, D. J.; Brenner, A. B.; Ditta, J. L.; Mattson, R. J.; Mattson, G. K.; Molski, T. F.; Macor, J. E. Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs) Bioorg. Med. Chem. Lett. 2005, 15, 1619-1621
6. Mattson, R. J.; Catt, J. D.; Denhart, D. J.; Deskus, J. A.; Ditta, J. L.; Higgins, M. A.; Marcin, L. R.; Sloan, C. P.; Beno, B. R.; Gao, Q.; Cunningham, M. A.; Mattson, G. K.; Molski, T. F.; Taber, M. T.; Lodge, N. J. Conformationally Restricted Homotryptamines. Indole Cyclopropylmethylamines as Selective Serotonin Reuptake Inhibitors J. Med. Chem. 2005, 48, 6023-6034
7. King, H. D.; Meng, Z.; Denhart, D.; Mattson, R.; Kimura, R.; Wu, D.; Gao, Q.; Macor, J. E. Enantioselective Synthesis of a Highly Potent Selective Serotonin Reuptake Inhibitor. An Application of Imidazolidinone Catalysis to the Alkylation of Indoles with an α,β-Disubstituted α,β- Unsaturated Aldehyde Org. Lett. 2005, 7, 3437-3440
8. King, H. D; Denhart, D. J.; Deskus, J. A.; Ditta, J. L.; Epperson, J. R.; Higgins, M. A.; Kung, J. E.; Marcin, L. R.; Sloan, C. P.; Mattson, G. K.; Molski, T. F.; Krause, R. G.; Bertekap, R. L.; Lodge, N. J.; Mattson, R. J.; Macor, J. E. Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor Bioorg. Med. Chem. Lett. 2007, 17, 5647-5651
9. Deskus, J. A.; Epperson, J. R.; Sloan, C. P.; Cipollina, J. A.; Dextraze, P.; Qian-Cutrone, J.; Gao, Q.; Ma, B.; Beno, B. R.; Mattson, G. K.; Molski, T. F.; Krause, R. G.; Taber, M. T.; Lodge, N. J.; Mattson, R. J. Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 3099-3104
10. Denhart, D. J.; Deskus, J. A.; Ditta, J. L.; Gao, Q.; King, H. D.; Kozlowski, E. S.; Meng, Z.; LaPaglia, M. A.; Mattson, G. K.; Molski, T. F.; Taber, M. T.; Lodge, N. J.; Mattson, R. J.; Macor, J. E. Conformationally restricted homotryptamines. Part 5: 3-(trans -2-aminomethylcyclopentyl)indoles as potent selective serotonin reuptake inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 4031-4033
11. Taber, M. T.; Wright, R. N.; Molski, T. F.; Clarke, W. J.; Brassil, P. J.; Denhart, D. J.; Mattson, R. J.; Lodge, N. J. Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130 Pharmacol., Biochem. Behav. 2005, 80, 521-528
12. 2O Synlett 1996, 1047-1048
13. Kaluzna, I. A.; Rozzell, J. D.; Kambourakis, S. Ketoreductases: stereoselective catalysts for the facile synthesis of chiral alcohols Tetrahedron: Asymmetry 2005, 16, 3682-3689
14. An analogous resolution of the CN-ketone 5a proved unsuccessful. We were unable to crystallize either of the diastereomers formed upon condensation of 5a with (1 S,2 S)-1,2-diphenylethane-1,2-diol.
15. The conformers of compounds 3 and 8a shown in Figure 2 were identified as follows: Initially, 7500 step Monte Carlo conformational searches with 2500 steps of PRCG (16) energy minimization per conformer using the OPLS2005 force-field (17) and GB/SA implicit water solvation model (18) were performed for compounds 3 and 8a in their N-protonated cationic forms using MacroModel version 9.5; Schrödinger, LLC: New York, NY, 2007. For each compound, the set of conformations obtained was then ranked in ascending order of OPLS2005 GB/SA energy and clustered using a non-hydrogen atom RMSD cutoff of 0.25 Å. The lowest energy conformer from each cluster was then optimized using density functional theory (DFT) calculations with the B3LYP functional, 6-31+G* basis set and a self-consistent reaction field implicit water solvation model. (19, 20) DFT calculations were performed with Jaguar version 7.0; Schrödinger, LLC: New York, NY, 2007. For compounds 3 and 8a, the lowest-energy DFT-optimized conformer that yielded a reasonable three-point overlay (see text) with the conformer of sertraline shown in Figure 5a of reference 6 was selected.
16. Polak, E.; Ribiere, G. Note sur la convergence de méthodes de directions conjuguées Rev. Fr. Autom. Inf. Rech. Oper., Ser. Rouge 1969, 16, 35-43
17. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids J. Am. Chem. Soc. 1996, 118, 11225-11236
18. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. A. Semianalytical treatment of solvation for molecular mechanics and dynamics J. Am. Chem. Soc. 1990, 112, 6127-6129
19. For details of the B3LYP DFT functional and implicit solvation method used see: Jaguar 7.0 User Manual; Schrodinger, LLC: New York, NY, 2007, and references therein.
20. Hehre, W. J.; Radom, L.; Schleyer, P. v. R.; Pople, J. A. Ab Initio Molecular Orbital Theory; John Wiley & Sons: New York, 1986; Chapter 4.